Regulators at the FDA have reiterated concerns that Replimmune does not have adequate data to support an approval of its ...

One year after launching the CMS Health Tech Ecosystem, officials convened in D.C. to celebrate the Trump administration ...

The big takeaway from the recent Alzheimer’s Association International Conference in London is an economic message: Dementia ...

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Rarely has a new technology so squarely ...

Bontle Moka-Moliki starts and ends every day in pain. The 32-year-old Atlanta resident was diagnosed with endometriosis in 2019. A year later came fibroids. Then in 2024 she was diagnosed with a ...

Ahead of a hearing, the FDA raised questions about the benefits of a Duchenne treatment from Capricor Therapeutics, another ...

Oak Hill Bio, a new company backed by RA Capital and other investors, will take on Ultragenyx and Ionis in developing an ...

Emergency departments across America report dramatic increases in serious injuries from e-bikes and e-scooters,” write CHOP’s ...

Even as some medical schools heed health secretary Robert F. Kennedy Jr.’s call for more nutrition education, several told ...

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. Argenx said Monday it would buy ...

The world risks a resurgence of the HIV epidemic after international financing to combat the disease suffered a “profound ...

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. Sarepta Therapeutics, the bruised ...